Report
Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.
Underlyings
Acceleron Pharma Inc

Acceleron Pharma is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat diseases. The company has focused its research and development activities in three primary therapeutic areas: hematology, pulmonary and neuromuscular. The company's commercial product, REBLOZYL? (luspatercept-aamt) for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions. The company is also developing its key pulmonary program, sotatercept, for the treatment of patients with pulmonary arterial hypertension. The company is developing its neuromuscular candidate, ACE-083, which is designed for the treatment of focal muscle disorders.

Agilent Technologies Inc.

Agilent Technologies is engaged in life sciences, diagnostics and applied chemical markets. The company's segments are: Life Sciences and Applied Markets Business, which provides instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products; Diagnostics and Genomics Business, which includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses; and Agilent CrossLab Business, which spans the entire lab with its consumables and services portfolio to improve customer outcomes.

Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. The company has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, the company has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.

Astec Industries Inc.

Astec Industries designs, engineers, manufactures and markets equipment and components used primarily in road building and related construction activities as well as other products. The company also manufactures certain equipment and components unrelated to road construction, including equipment for the mining, quarrying, construction and demolition industries and port and rail yard operators; gas and oil drilling rigs; water well and geothermal drilling rigs; industrial heat transfer equipment; commercial whole-tree pulpwood chippers; horizontal grinders; blower trucks; concrete plants; wood pellet plants; commercial and industrial burners; and combustion control systems.

AstraZeneca PLC ADS

AudioCodes Ltd.

AudioCodes designs, develops and sells products and services for voice and data over packet networks. Voice over packet, or VoP, networks consist of key network elements such as software switches, application servers, Internet protocol (IP) phones, media gateways and session border controllers (SBC). Co.'s products primarily provide the media gateway and SBC element in the network, as well as voice over Internet protocol, or VoIP, end-points such as IP Phones and VoIP mobile clients. Multi-service business routers integrate media gateway functionality with data routing and network access. The media gateways connect legacy and IP networks.

Bio-Techne Corporation

Bio-Techne and its subsidiaries develop, manufacture and sell biotechnology life science reagents, instruments and services for the research and clinical diagnostic markets.Co.'s segments: Protein Sciences, which developes and manufactures purified proteins and reagent solutions, cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies; and Diagnostics and Genomics, which develops and manufactures diagnostic products, including Food and Drug Administration-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for Original Equipment Manufacturer.

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

Bristol-Myers Squibb Company

Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.

Caterpillar Inc.

Caterpillar is a manufacturer of construction and mining equipment, diesel and natural gas engines, industrial gas turbines and diesel-electric locomotives. The company segments include: Construction Industries, which supports customers using machinery in infrastructure, forestry and building construction; Resource Industries, which supports customers using machinery in mining, heavy construction, quarry and aggregates, waste and material handling applications; Energy and Transportation, which supports customers in oil and gas, power generation, marine, rail and industrial applications, including Cat? machines; and Financial Products, which provides financing and related services.

China Petroleum & Chemical Corp. ADS

Ciena Corporation

Ciena is a networking systems, services and software company, providing solutions that enable a range of network operators to deploy and manage networks that deliver services to businesses and consumers. The company provides hardware, software and services that support the transport, switching, aggregation, service delivery and management of video, data and voice traffic on communications networks. The company's solutions are used by communications service providers, cable and multiservice operators, Web-scale providers, submarine network operators, governments, enterprises, research and education institutions and other network operators.

CytomX Therapeutics Inc.

CytomX Therapeutics is clinical-stage, oncology-focused biopharmaceutical company with a class of investigational antibody therapeutics based on its Probody? technology platform the treatment of cancer. The company uses its platform to create proprietary cancer immunotherapies against clinically-validated targets. The company's two programs, CX-072, a wholly owned PD-L1-targeting Probody therapeutic and CX-2009, wholly owned CD166-targeting Probody drug conjugate. Both CX-072 and CX-2009 are part of PROCLAIM (Probody Clinical Assessment in Man), an international umbrella clinical trial program that provides clinical trial sites with access to the company's novel therapies under one central protocol.

Cytosorbents

Cytosorbents is engaged in critical care immunotherapy, investigating and commercializing its CytoSorb blood purification technology to reduce uncontrolled inflammation in hospitalized patients around the world, to prevent or treat multiple organ failure in life-threatening illnesses and cardiac surgery. CytoSorb, the company's primary product, is approved in the European Union as an extracorporeal cytokine filter and is designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery.

Dr. Reddy's Laboratories Ltd. ADS

Fortinet Inc.

Fortinet provides cybersecurity solutions. The company's product offerings consist of its FortiGate product family and its non-FortiGate products. The company's FortiGate hardware and software licenses are sold with a set of security services. These security services are enabled by FortiGuard, which provides threat research and artificial intelligence capabilities from a global cloud network to deliver protection services to each FortiGate appliance. The company's non-FortiGate products include the Fortinet Security Fabric (such as FortiAP, FortiAnalyzer, FortiSwitch and FortiManager), certain cloud security products (such as virtual machines and cloud services) and other products.

Genmab A/S

Hill-Rom Holdings Inc.

Hill-Rom Holdings is a medical technology company. The company's reportable segments are: Patient Support Systems, which include a variety of frames and surfaces (such as medical surgical (med-surg) beds, intensive care unit beds, and bariatric patient beds), patient mobility solutions (such as lifts and other devices used to move patients), non-invasive therapeutic products and surfaces, and its information technologies and software solutions; Front Line Care, which includes its patient monitoring and diagnostics products and its respiratory health products; and Surgical Solutions, which include tables, lights, and pendants utilized within the surgical setting.

Horizon Therapeutics Public Limited Company

IDEX CORP

IDEX is an applied solutions business that sells pumps, valves, flow meters and other fluidics systems and components and engineered products. The company's segments are: Fluid and Metering Technologies, which designs, produces and distributes positive displacement pumps, flow meters, injectors and other fluid-handling pump modules and systems; Health and Science Technologies, which designs, produces and distributes fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems; and Fire and Safety/Diversified Products, which designs, produces and distributes firefighting pumps, valves and controls, rescue tools, and lifting bags.

Ingredion Incorporated

Ingredion provides ingredients solutions. The company turns corn, tapioca, potatoes, grains, fruits, and vegetables into ingredients and biomaterials for the food, beverage, brewing and other industries. The company's product lines include starches and sweeteners, animal feed products and edible corn oil. The company's starch-based products include both food-grade and industrial starches, and biomaterials. The company's sweetener products include glucose syrups, maltose syrups, fructose corn syrup, caramel color, dextrose, polyols, maltodextrins, and glucose and syrup solids. The company's products are derived from the processing of corn and other starch-based materials, such as tapioca, potato, and rice.

Innoviva Inc.

Innoviva is a company with a portfolio of royalties that include respiratory assets. The company's Long-Acting Beta2 Agonist (LABA) collaboration has developed the combination products: RELVAR? /BREO? ELLIPTA?, a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF); ANORO? ELLIPTA?, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI; and RELEGY? ELLIPTA? (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA and LABA.

Inphi Corporation

Inphi is a provider of analog and mixed signal semiconductor solutions for the communications and datacenter markets. The company's analog and mixed signal semiconductor solutions provide an interface between analog and mixed signals and digital information in systems such as telecommunications transport systems, enterprise networking equipment and datacenters. The company has a range of products in its portfolio, including products that have commercially shipped, products for which the company has shipped engineering samples and products under development, that perform a range of functions such as amplifying, encoding, multiplexing, demultiplexing, and retiming signals at speeds up to 400 Gbps.

Kala Pharmaceuticals Inc.

Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using its AMPPLIFY? Mucus Penetrating Particles drug delivery technology, with a focus on the treatment of eye diseases. The company's approved ocular corticosteroid product, INVELTYS? (loteprednol etabonate ophthalmic suspension) is used for the treatment of post-operative inflammation and pain. The company is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The company is evaluating compounds in its receptor Tyrosine Kinase Inhibitor program that inhibit the vascular endothelial growth factor pathway for the treatment of a number of retinal diseases.

NuVista Energy Ltd.

Nuvista Energy is engaged in the exploration of, and the acquisition, development and production of oil and natural gas reserves and assets related thereto in the Provinces of Alberta, British Columbia and Saskatchewan.

Phibro Animal Health Corporation Class A

Phibro Animal Health is an animal health and mineral nutrition company. The company develops, manufactures and markets products for a range of food animals including poultry, swine, beef and dairy cattle and aquaculture. The company's products include animal health products such as antibacterials, anticoccidials, nutritional products and vaccines. The company's Animal Health segment also includes antibacterials and other processing aids in the ethanol fermentation industry. The company's mineral nutrition products fortify the animal's diet and help maintain optimal health. The company also manufactures and markets ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, the company develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the U.S. and Canada) and in Australia and certain other international markets. The company's portfolio of OTC Healthcare products includes, among others, DenTek oral care products, Monistat women's health products, Nix lice treatment products, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, Luden's throat drops, BC and Goody's pain relievers and Debrox earwax remover.

Rio Tinto PLC ADS (Mexico)

Seagate Technology PLC

Seagen Inc.

Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. The company is commercializing ADCETRIS?, or brentuximab vedotin, for the treatment of several types of lymphoma. The company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of the company's programs, including ADCETRIS, are based on its antibody-drug conjugate (ADC), technology. The company's late-stage pipeline includes two ADCs and an oral tyrosine kinase inhibitor, for solid tumors that are in clinical trials designed to support applications for potential regulatory approvals.

Silgan Holdings Inc.

Silgan Holdings is a holding company. Through its subsidiaries, the company manufactures rigid packaging for consumer goods products. The company operates three businesses; its metal container business, which used primarily by processors and packagers for food products, such as vegetables, soup, proteins, tomato based products, adult nutritional drinks and fruit ; its closures business, which manufactures metal and plastic closures and dispensing systems for food and beverage and health care products; and its plastic container business, which manufactures custom designed and stock plastic containers for personal care and health care products, including containers for mouthwash, shampoos, and conditioners.

Telefonaktiebolaget LM Ericsson

Travere Therapeutics Inc.

Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. The company sells the following three products: Chenodal? (chenodeoxycholic acid), which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age; Cholbam? (cholic acid), which is for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders; and Thiola? (tiopronin), which is for the prevention of cystine (kidney) stone formation in patients with homozygous cystinuria.

United Therapeutics Corporation

United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.

Vanguard Consumer Discretionar

Vista Outdoor Inc

Vista Outdoor is a designer, manufacturer and marketer of consumer products in the outdoor sports and recreation markets. The company's Outdoor Products product lines are action sports, archery/hunting accessories, outdoor cooking, golf, hydration products, optics, shooting accessories and tactical products. The Shooting Sports segment designs, develops, produces, and sources ammunition and firearms for the hunting and sport shooting markets, as well as ammunition for local law enforcement, the U.S. government and international markets. The Shooting Sports product lines include centerfire ammunition, rimfire ammunition, shotshell ammunition, reloading components, and firearms.

Provider
Vermilion Research
Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

Analysts
Dave Nicoski

Ross LaDuke

Other Reports on these Companies
Other Reports from Vermilion Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch